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Breast cancer is the top cancer among women, and its incidence is increasing worldwide.
Although the mortality tends to decrease due to early detection and treatment, there is
great variability in the rates of clinical response and survival, which makes breast can-
cer one of the most appealing targets for pharmacogenomic studies. The recognition that
functional CYP2D6 polymorphisms affect tamoxifen pharmacokinetics has motivated the
attempts of using CYP2D6 genotyping for predicting breast cancer outcomes. In addition
to tamoxifen, the chemotherapy of breast cancer includes combinations of cytotoxic drugs,
which are substrates for various xenobiotic metabolizing enzymes. Because of these drugs’
narrow therapeutic window, it has been postulated that impaired biotransformation could
lead to increased toxicity. In the present review, we performed a systematic search of all
published data exploring associations between polymorphisms in xenobiotic metabolizing
enzymes and clinical outcomes of breast cancer. We retrieved 43 original articles involv-
ing either tamoxifen or other chemotherapeutic protocols, and compiled all information
regarding response or toxicity. The data indicate that, although CYP2D6 polymorphisms
can indeed modify tamoxifen pharmacokinetics, CYP2D6 genotyping alone is not enough
for predicting breast cancer outcomes. The studies involving other chemotherapeutic pro-
tocols explored a great diversity of pharmacogenetic targets, but the number of studies for
each functional polymorphism is still very limited, with usually no confirmation of positive
associations. In conclusion, the application of pharmacogenetics to predict breast cancer
outcomes and to select one individual’s chemotherapeutic protocol is still far from clinical
routine. Although some very interesting results have been produced, no clear practical
recommendations are recognized yet.
Keywords: breast cancer, gene polymorphisms, xenobiotic metabolizing enzymes, hormone therapy,
chemotherapy, efficacy, toxicity
INTRODUCTION
Breast cancer is the most frequent type of cancer in women (Jemal
et al., 2011), and the second leading cause of cancer-related death
in women worldwide (DeSantis et al., 2011). The incidence rates
of breast cancer are increasing both in developed and in develop-
ing countries (Ferlay et al., 2010), whereas the mortality rates have
decreased in the last decade [World Health Organization (WHO),
2004; Ferlay et al., 2010; DeSantis et al., 2011; Jemal et al., 2011],
probably because of the investments in early detection and in
new pharmacological approaches (Berry et al., 2005). Although
the recent decrease in the mortality rates proves the efficacy of
the current therapeutic protocols, the optimization of available
therapies is crucial. Most anticancer drugs are highly toxic, and
many patients suffer with adverse reactions that might be persis-
tent throughout the treatment, and sometimes even irreversible.
In addition to their obvious impact in patients’ quality of life, drug
toxicities may also require dose delays, treatment modifications, or
even treatment interruption, contributing to the great variability
that is usually observed in breast cancer clinical outcomes. This
scenario makes breast cancer one of the most appealing targets for
evaluation of pharmacogenomic strategies toward personalized
medicine.
The current treatment of breast cancer consists of combinations
of surgery and adjuvant or neoadjuvant therapeutic approaches,
including radiotherapy, cytotoxic chemotherapy, hormonal ther-
apy, and targeted therapy. The treatment choice is routinely based
on the estimated risk of recurrence, considering the clinical stage at
diagnosis and molecular predictive factors (Soerjomataram et al.,
2008). Nevertheless, breast cancer is a very heterogeneous disease,
with a continuous grading in tumor histology (Hayes et al., 2001),
different cellular origins (Anderson and Matsuno, 2006), and great
molecular diversity (Danova et al., 2011), which make prognos-
tic estimates a difficult task, especially in early-stage tumors. In
an attempt to improve the classical pathology-driven classifica-
tion of breast tumors, a series of efforts are currently in course,
including the description of gene expression patterns (Perou et al.,
2000; Sørlie et al., 2001), and of genomic signatures (Banerji et al.,
2012; Nik-Zainal et al., 2012; Stephens et al., 2012). In addition
to molecular variations in the tumor, the individual genetic diver-
sity may also contribute for the great heterogeneity in treatment
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outcomes. Thus, inherited sequence variations (polymorphisms)
in genes involved in the pharmacokinetics and pharmacodynam-
ics of anticancer drugs may affect both their efficacy and safety
(O’Donnell and Ratain, 2012; Ruiz et al., 2012).
The chemotherapy of breast cancer includes different options
of drug combinations. Anthracycline-based protocols have
become the standard adjuvant and neoadjuvant chemotherapy
for most patients in view of clinical evidences of improved effi-
cacy in comparison to other previously used protocols (Hassan
et al., 2010). More recently, taxanes, such as docetaxel or pacli-
taxel, were added to anthracycline-based protocols, further reduc-
ing the risk of recurrence (De Laurentiis et al., 2008; Martín
et al., 2010; Jacquin et al., 2012). The most usual protocols for
breast cancer chemotherapy nowadays are: docetaxel, doxoru-
bicin, and cyclophosphamide (TAC); docetaxel, epirubicin, and
cyclophosphamide (TEC); cyclophosphamide, doxorubicin, and
5-fluorouracil, followed by docetaxel (CAF-T); doxorubicin and
cyclophosphamide (AC); and doxorubicin and cyclophosphamide,
followed by paclitaxel or docetaxel (AC-P or AC-T). The older pro-
tocol cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
is also still used.
Cytotoxic antineoplastic drugs have narrow therapeutic win-
dow, and small variations in their plasma concentrations may lead
to clinically significant toxicity. Taxanes, for example, may cause
severe bone marrow dysfunction, and their toxic effects present
great interpatient variability, which appear to be due to interindi-
vidual differences in pharmacokinetic parameters (Engels et al.,
2011). Accordingly, the biotransformation of taxanes is mainly
mediated by hepatic CYP450s, which may occur in different iso-
forms, with distinct functional activities, as a consequence of
polymorphisms in their coding genes. Doxorubicin and epiru-
bicin may cause severe cardiotoxicity (Doyle et al., 2005; Pinder
et al., 2007; Gianni et al., 2008) and bone marrow dysfunction
(Hershman et al., 2007; Patt et al., 2007). Their biotransformation
includes reductions by carbonyl reductases (CBR1 and CBR3) and
by aldoketoreductases (AKR1A1 and AKR1C3; Lal et al., 2010).
Epirubicin also undergoes conjugation by uridine diphosphate-
glucuronosyltransferase 2B7 (UGT2B7; Innocenti et al., 2001).
Finally, glutathione (S)-transferases (GSTs) may also participate
to detoxification. Like the CYP450s, all these xenobiotic metabo-
lizing enzymes are coded by polymorphic genes, which make them
potential targets for pharmacogenomic evaluations.
In addition to the cytotoxic antineoplastic drugs, tamoxifen
is perhaps the most appealing target for breast cancer pharma-
cogenomics. It was approved by the FDA in 1977, and since
then, it is still the drug with the most striking effect on patients’
survival, reducing the annual risk of recurrence by 39% after a 5-
year treatment [Early Breast Cancer Trialists Collaborative Group
(EBCTCG), 2005]. The antitumor effects of tamoxifen are medi-
ated by selective modulation of the estrogen receptor, which can
be detected in more than two thirds of breast tumors, and to con-
sequent inhibition of estrogen-dependent cell proliferation. How-
ever, in spite of the undisputable efficacy and long-term benefits of
tamoxifen for breast cancer patients, there is great interindividual
variability in the degree of response. Thus, approximately half of
the estrogen receptor-positive tumors do not respond to tamoxifen
therapy (Jaiyesimi et al., 1995; Osborne, 1998; Buzdar, 2001), and
the 15-year recurrence probability in early breast cancer patients
treated with tamoxifen for 5 years is approximately one third [Early
Breast Cancer Trialists Collaborative Group (EBCTCG), 2005].
The great interindividual variability observed in the degree of
response to tamoxifen can be ascribed to different causes, includ-
ing failures in patient adherence, drug interactions, and genetic
variations affecting tamoxifen pharmacokinetics (Hoskins et al.,
2009). This variability is of special concern in premenopausal
women, who cannot receive aromatase inhibitors, and therefore
have less therapeutic options. Thus, it seems crucial to find strate-
gies to ensure tamoxifen response, minimize, or predict individual
variability, and improve disease outcomes. Besides the interpa-
tient variability in the degree of response, another motivation
for pharmacogenomic studies would be tamoxifen safety. The
main concern refers to the risk of endometrial cancer and of
thromboembolic events, although these are quite rare events
(Fisher et al., 1998). The most common side effect of tamox-
ifen therapy is hot flushes, which are intrinsically correlated with
tamoxifen’s antiestrogenic activity. Although hot flushes do not
represent a life threat, and might become more tolerable with
therapy continuation, they can be so intense that patients stop
tamoxifen use.
Tamoxifen is considered a prodrug, with very little affinity
for the estrogen receptor in its original structure (Coezy et al.,
1982). The pharmacological actions of tamoxifen are most likely
due to its metabolites (Coezy et al., 1982; Robertson et al.,
1982), which are generated in the liver by numerous phase I
and II reactions (Mürdter et al., 2011). The major metabo-
lite is N -desmethyl-tamoxifen, which is generated by CYP3A4/5
and accounts for approximately 90% of tamoxifen metabolites
(Desta et al., 2004). However, N -desmethyl-tamoxifen shows lit-
tle affinity for the estrogen receptor when compared to two other
metabolites, 4-hydroxy-tamoxifen and 4-hydroxy-N -desmethyl-
tamoxifen (endoxifen; Coezy et al., 1982; Jordan, 1982; Robertson
et al., 1982). Because 4-hydroxy-tamoxifen and endoxifen have
similar potencies in suppressing estrogen-dependent cell prolif-
eration, but the latter appears to be generated in higher concen-
trations, endoxifen is believed to be the major active metabolite
in vivo (Johnson et al., 2004; Lim et al., 2005). Endoxifen genera-
tion is mainly dependent on CYP2D6 activity (Desta et al., 2004),
and initial observations suggested that genetic polymorphisms in
its coding gene, CYP2D6, could affect the activity of CYP2D6,
resulting in reduced plasma level of endoxifen (Jin et al., 2005).
Corroborating this notion, CYP2D6 polymorphisms responsible
for reduced CYP2D6 activity were associated with worse breast
cancer outcomes in postmenopausal estrogen receptor-positive
patients treated with tamoxifen (Goetz et al., 2005). These results
prompted the FDA to recommend, in 2006, an update in the
tamoxifen package insert, alerting for the increased risk of breast
cancer recurrence in patients who are CYP2D6 poor metabolizers.
The awareness of the potential impact of CYP2D6 polymor-
phisms in tamoxifen pharmacokinetics and pharmacodynamics
has motivated a series of pharmacogenomic studies, designed to
explore the possibility of using CYP2D6 genotyping for predicting
clinical outcomes in breast cancer patients receiving tamoxifen.
According to more recent data, it seems clear that genetic poly-
morphisms that modulate CYP2D6 activity can indeed modify
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endoxifen plasma levels (Kiyotani et al., 2010; de Graan et al., 2011;
Irvin et al., 2011; Lim et al., 2011; Mürdter et al., 2011). However,
the impact of such pharmacokinetic changes on the individual
degree of response to tamoxifen is less clear, and CYP2D6 geno-
typing alone has been not enough for predicting breast cancer
outcomes in clinical settings (Abraham et al., 2010; Rae, 2011;
Regan et al., 2012). It appears, thus, that the pharmacological
actions of tamoxifen may be more complex than initially thought,
with its antiestrogenic activity being dependent not on a single
metabolite, but on a composite action of them (Rae et al., 2011).
As a consequence of this new assumption, other genetic poly-
morphisms affecting the pharmacokinetics of tamoxifen might
have additional influences on breast cancer outcomes, and should
also be considered in pharmacogenomic studies. Likewise, there
might be combined influences of genetic polymorphisms on the
pharmacokinetics/dynamics of both tamoxifen and other cyto-
toxic chemotherapeutic drugs, which would require much more
complex study designs for evaluation of their impact in clinical
settings.
In the present review, we aimed to compile all information
available on pharmacogenomic studies involving polymorphisms
in xenobiotic metabolizing enzymes and their consequences in
clinical outcomes of breast cancer. The analyzed studies explore
either tamoxifen or the antineoplastics used in chemotherapy.
Instead of focusing on selected positive associations, we performed
a systematic review of all published data, evaluating the reported
effects on both response and toxicity, as well as all the recorded
information of null associations.
MATERIALS AND METHODS
A systematic review of the literature data was conducted,which was
performed via electronic search of the MEDLINE database (avail-
able at PUBMED), and included articles available until August
2012. The search terms were selected using the controlled vocab-
ulary MeSH for the PubMed database. The main search was as
follows: [“polymorphism, genetic” (MeSH Terms)] AND [“breast
neoplasms” (MeSH Terms)] AND [enzyme (Text Word) OR
“enzymes” (MeSH Terms)] AND [breast cancer (Title/Abstract)]
AND (xenobiotic OR drug) NOT [“Review” (Publication Type)].
The following filters were used: Published in the last 10 years;
Humans; English; Female.
All abstracts were retrieved, and were used for selection of arti-
cles to be used in the review. The pre-defined inclusion criteria
were: original articles, including clinical trials, prospective, or ret-
rospective observational studies, describing correlations between
polymorphisms in xenobiotic metabolizing enzymes and any clin-
ical response or outcome of breast cancer patients under therapeu-
tic treatment. The exclusion criteria were: letters, commentaries,
editorials, or case reports; studies involving only the susceptibil-
ity of developing cancer; studies involving only drug transporters
or other enzymes not responsible for xenobiotic metabolism;
studies involving only pharmacokinetic analyses or correlation
with histopathological features, without evaluation of clinical
outcomes.
Two reviewers performed the selection of articles to be included
in the review according to previously defined inclusion and exclu-
sion criteria, and extracted information for data compilation.
A third reviewer examined the lists of selected and excluded arti-
cles in order to confirm the eligibility, and checked all the extracted
information.
The compiled information was evaluated separately for tamox-
ifen and for other chemotherapeutic protocols, and focused on the
associations between polymorphisms and drug efficacy or drug
safety. All the null associations were also collected, compiled, and
analyzed.
RESULTS
The literature search resulted in 158 abstracts among the biblio-
graphic references from PUBMED. The abstract reading led to the
selection of 30 original articles involving tamoxifen use, and 22
original articles involving any kind of breast cancer chemother-
apy. The excluded items (106) consisted of non-original articles
(4), articles not involving xenobiotic metabolizing enzymes (85),
articles evaluating only the susceptibility to breast cancer (10), arti-
cles evaluating only the correlation with histopathological features
(3), articles involving only pharmacokinetic analyses (2), 1 article
evaluating clinical outcomes not related to breast cancer treat-
ment, and 1 article not involving humans. Among the 49 selected
abstracts, 2 articles could not be retrieved, and 7 articles did not fit
the inclusion criteria. The excluded articles after full-text reading
were: 2 articles not involving xenobiotic metabolizing enzymes,
1 article based on previously published data, 1 article analyzing
breast cancer patients together with other cancer patients, 1 article
involving only pharmacokinetic analyses, 1 article evaluating clin-
ical outcomes not related to breast cancer treatment, and 1 article
which was retracted. The selected articles consisted of 23 original
studies involving tamoxifen use, and 20 original studies involving
other chemotherapeutic protocols (Figure 1).
The selected studies were mostly based on prospective, obser-
vational designs, and focused on the evaluation of different breast
cancer outcomes, defined either as primary or secondary end-
points. Some studies also included pharmacokinetic evaluations or
other endpoints not directly related to breast cancer treatment. The
extracted information was restricted to polymorphisms in xeno-
biotic metabolizing enzymes and to any clinical outcome directly
correlated to breast cancer treatment. The results are distributed
in five Tables: Tables 1 and 2 present the compiled data involv-
ing tamoxifen treatment, and comprise results on both efficacy
and safety. Table 1 presents only statistically significant associa-
tions, whereas Table 2 presents only null associations. Tables 3–5
present the compiled data involving any adjuvant, neoadjuvant, or
palliative chemotherapeutic protocol. Table 3 presents the signifi-
cant associations involving efficacy outcomes, Table 4 presents any
significant association involving toxicities, and Table 5 presents
all reported null associations, involving either efficacy or safety
outcomes.
Among the 20 studies involving tamoxifen use, 16 explored the
effects of CYP2D6 polymorphisms, either considering polymor-
phisms individually or in their combined genotypes and expected
phenotypes. The other four articles evaluated polymorphisms in
other genes different from CYP2D6. Thus, Nowell et al. (2002)
examined the relationship between the SULT1A1∗2 allele and sur-
vival in a cohort of 337 women (160 receiving tamoxifen); Tucker
et al. (2005) evaluated the impact of CYP3A5 polymorphisms on
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FIGURE 1 | Flow chart of the systematic review of literature data.
tamoxifen side effects in 98 postmenopausal women; Jernström
et al. (2009) investigated the frequency of CYP2C8 and CYP2C9
polymorphisms in relation to disease-free survival in a prospec-
tive series of 652 breast cancer patients (297 receiving tamoxifen),
and Ruiter et al. (2010) evaluated the impact of CYP2C19∗2 and
CYP2C19∗3 on breast cancer mortality rate in 215 breast cancer
patients (80 using tamoxifen). Among the 16 studies evaluating
CYP2D6 polymorphisms, 7 studies also analyzed other genes:
Nowell et al. (2005) analyzed UGT2B15 polymorphisms; Weg-
man et al. (2005) examined variants of SULT1A1; Wegman et al.
(2007) evaluated CYP3A5, SULT1A1, and UGT2B15; Okishiro
et al. (2009) analyzedCYP2C19 ; Kiyotani et al. (2010) did not eval-
uate polymorphisms involving xenobiotic metabolizing enzymes,
but examined gene polymorphisms affecting drug transporters
(ABCB1, ABCC2, ABCG2); and Moyer et al. (2011) examined
SULT1A1 and CYP2C19 polymorphisms.
The compiled results in Table 1 indicate that some functional
polymorphisms affecting the enzymatic activities of CYP2D6,
CYP3A5, CYP2C8, CYP2C19, SULT1A1, or UGT2B15 could sig-
nificantly affect breast cancer outcomes. Thus, CYP3A5∗3 and
CYP2C19∗2 seem to be beneficial with regards to the risk of recur-
rence or to breast cancer-specific survival, respectively. All the
other polymorphisms with reported significant effects on breast
cancer clinical outcomes, i.e., CYP2C8∗3, CYP2D6∗4, CYP2D6∗6,
CYP2D6∗10, SULT1A1∗2, and UGT2B15∗2, were associated with
an apparent worse response to tamoxifen, resulting in higher risk
of tumor recurrence, shorter breast cancer-specific survival, or
shorter overall survival.
With regards to CYP2D6∗4, the work by Wegman et al. (2007)
represents an exception, since it shows an apparent beneficial effect
of the genotype CYP2D6∗1/∗4 in relation to recurrence-free sur-
vival. This apparently protective effect, however, was not seen for
patients homozygous for the allele ∗4, who were similar to patients
with the wild-type genotype in relation to recurrence-free survival.
Although there are no other reports suggesting any beneficial effect
of CYP2D6 polymorphisms in relation to breast cancer outcomes,
there is much inconsistency in the supposed detrimental effects of
the variant alleles with regards to the risk of recurrence. Thus, only
Bijl et al. (2009), with a very limited number of patients, reported
an apparent trend between heterozygous and homozygous variants
of the allele ∗4. Goetz et al. (2005) only found significant effects
when comparing the homozygous variant genotype ∗4/∗4 to the
homozygous wild-type genotype ∗1/∗1. All the other published
studies involving CYP2D6∗4 indicate no significant effect for the
variant allele, either in heterozygosis or in homozygosis (Table 2).
The lack of significant independent effect of the allele ∗4 cannot
be attributed to low statistical power, since it was confirmed by the
two largest studies (Abraham et al., 2010; Regan et al., 2012). The
study by Abraham et al. (2010) also show no significant effects on
breast cancer outcomes regarding the CYP2D6 variant alleles ∗5,
∗9, ∗10, and ∗41. The lack of significant effects with the variant
genotypes of CYP2D6∗10 had already been reported by Okishiro
et al. (2009) and Toyama et al. (2009).
Other studies analyzed multipleCYP2D6 polymorphisms (alle-
les ∗3, ∗4, ∗5, ∗6, ∗7, ∗10, ∗14, ∗21, ∗36–∗36, ∗41) in different
combinations, and, based on their expected functional impact on
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Table 2 | Null associations between polymorphisms in xenobiotic metabolizing enzymes and breast cancer outcomes after tamoxifen treatment.
Gene SNP Reference Population Design N Compared groupsa Outcome
CYP2D6 *4 Goetz et al. (2005) Adjuvant Cohort 223 *1/*1 or *1/*4 vs. *4/*4 RFS
*1/*1 or *1/*4 vs. *4/*4 DFS
*1/*1 or *1/*4 vs. *4/*4 Hot flushes
Nowell et al. (2005) Adjuvant Case-cohort 162 *1/*1 vs. *4 Carrier PFS
Wegman et al. (2005) Adjuvant Cohort 112 *1/*1 vs. *1/*4 or *4/*4 RFS
Wegman et al. (2007) Adjuvant Cohort 677 *1/*1 vs. *4/*4 RFS
*1/*1 vs. *1/*4 or *4/*4 RFS
Abraham et al. (2010) Adjuvant Case-cohort 3155 *1/*1 vs. *4 Carrier BCSS
Regan et al. (2012) Adjuvant Cohort 4393 *1/*1 vs. *4/*4 BCFI
*1/*1 vs. *1/*4 BCFI
van Schaik et al. (2011) Palliative Cohort 499 *1/*1 vs. *4 Carrier TTF
*5 Abraham et al. (2010) Adjuvant Case-cohort 3155 *1/*1 vs. *5 Carrier BCSS
*9 Abraham et al. (2010) Adjuvant Case-cohort 3155 *1/*1 vs. *9 Carrier BCSS
*10 Okishiro et al. (2009) Adjuvant Cohort 173 *1/*1 or *1/*10 vs. *10/*10 RFS
*1/*1 or *1/*10 vs. *10/*10 Bone
mineral
density
*1/*1 or *1/*10 vs. *10/*10 Total
cholesterol
*1/*1 or *1/*10 vs. *10/*10 Endometrial
thickness
(1 year TAM)
Toyama et al. (2009) Adjuvant Cohort 156 *1/*1 vs. *1/*10 or *10/*10 DFS
*1/*1 vs. *1/*10 or *10/*10 DFS
*1/*1 vs. *1/*10 or *10/*10 BCSS
Abraham et al. (2010) Adjuvant Case-cohort 3155 *1/*1 vs. *10 Carrier BCSS
Xu et al. (2008) Adjuvant Cohort 152 *1/*1 vs. *10 Carrier 5-Year DSS
*41 Abraham et al. (2010) Adjuvant Case-cohort 3155 *1/*1 vs. *41 Carrier BCSS
Combined
CYP2D6
genotypes
Abraham et al. (2010)b Adjuvant Case-cohort 3155 *1/*1 vs. PM or IM BCSS
*1/*1 vs. PM BCSS
Regan et al. (2012)d Adjuvant Cohort 4393 EM vs. PM BCFI
EM vs. IM BCFI
EM vs. PM or IM BCFI
EM vs. PM Hot flushes
EM vs. IM Hot flushes
EM vs. PM/IM Hot flushes
Teh et al. (2012)c Non-
palliative
Cohort 95 EM vs. Het-IM RFS
Newman et al. (2008)e Adjuvant Cohort 115 *1/*1 vs. PM TTR
*1/*1 vs. PM OS
CYP2C8 *4 Jernström et al. (2009) Adjuvant Cohort 297 *1/*1 vs. *1/*4 or *4/*4 BCSS
CYP2C9 *2 Jernström et al. (2009) Adjuvant Cohort 297 *1/*1 vs. *1/*2 or *2/*2 BCSS
*3 *1/*1 vs. *1/*3 or *3/*3 BCSS
CYP2C19 *2 and
*3
Okishiro et al. (2009) Adjuvant Cohort 173 *1/*1, *1/*2, or *1/*3 vs. *2/*2, *2/*3, or *3/*3 RFS
*1/*1, *1/*2, or *1/*3 vs. *2/*2, *2/*3, or *3/*3 Bone
mineral
density
*1/*1, *1/*2, or *1/*3 vs. *2/*2, *2/*3, or *3/*3 Total
cholesterol
(Continued)
www.frontiersin.org January 2013 | Volume 3 | Article 329 | 7
Vianna-Jorge et al. Polymorphisms in XME and breast cancer
Table 2 | Continued
Gene SNP Reference Population Design N Compared groupsa Outcome
*1/*1, *1/*2, or *1/*3 vs. *2/*2, *2/*3, or *3/*3 Endometrial
thickness
(1 year TAM)
*2 van Schaik et al. (2011) Palliative Cohort 499 *1/*1 vs. *2 Carrier DFS
*17 Moyer et al. (2011) All incident
users
Cohort 190 *1/*1 vs. *1/*17 or *17/*17 DFS
van Schaik et al. (2011) Palliative Cohort 499 *1/*1 vs. *17 Carrier TTF
CYP3A5 *3 Goetz et al. (2005) Adjuvant Cohort 223 *1/*1 or *1/*3 vs. *3/*3 RFS
*1/*1 or *1/*3 vs. *3/*3 DFS
*1/*1 or *1/*3 vs. *3/*3 Hot flushes
Tucker et al. (2005) Adjuvant Cohort 98 *1/*1 vs. *1/*3 or *3/*3 Nausea
*1/*1 vs. *1/*3 or *3/*3 Migraines
*1/*1 vs. *1/*3 or *3/*3 Depression
*1/*1 vs. *1/*3 or *3/*3 Vaginal
discharge
*1/*1 vs. *1/*3 or *3/*3 Vaginal
dryness
*1/*1 vs. *1/*3 or *3/*3 Insomnia
*1/*1 vs. *1/*3 or *3/*3 Hot flushes
*6 Tucker et al. (2005) Adjuvant Cohort 98 *1/*1 vs. *1/*6 or *6/*6 Nausea
*1/*1 vs. *1/*6 or *6/*6 Migraines
*1/*1 vs. *1/*6 or *6/*6 Depression
*1/*1 vs. *1/*6 or *6/*6 Vaginal
discharge
*1/*1 vs. *1/*6 or *6/*6 Vaginal
dryness
*1/*1 vs. *1/*6 or *6/*6 Insomnia
*1/*1 vs. *1/*6 or *6/*6 Hot flushes
SULT1A1 *2 Wegman et al. (2005) Adjuvant Cohort 112 *1/*1 vs. *1/*2 or *2/*2 RFS
Wegman et al. (2007) Adjuvant Cohort 677 *1/*1 vs. *1/*2 or *2/*2 RFS
Copy
number
Moyer et al. (2011) All incident
users
Cohort 190 ≤2 vs. >2 DFS
UGT1A8 *3 Ahern et al. (2011) Non-
palliative
Case-cohort 541 *1/*1 vs. *1/*3 or *3/*3 RFS
UGT2B7 *2 Ahern et al. (2011) Non-
palliative
Case-cohort 541 *1/*1 vs. *2/*2 RFS
UGT2B15 *2 Nowell et al. (2005) Adjuvant Case-cohort 162 *1/*1 vs. *1/*2 RFS
*1/*1 vs. *2/*2
Wegman et al. (2007) Adjuvant Cohort 677 *1/*1 vs. *1/*2, *2/*2 RFS
Ahern et al. (2011) Non-
palliative
Case-cohort 541 *1/*1 vs. *2/*2 RFS
Abbreviations: BCFI, breast cancer-free interval; BCSS, breast cancer-specific survival; DFS, disease-free survival; DSS, disease-specific survival; EM, extensive metab-
olizer; Het, heterozygous; Homo, homozygous; IM, intermediate metabolizer; PFS, progression-free survival; PM, poor metabolizer; RFS, recurrence-free survival;TTF,
time-to-treatment failure; V, variant alleles. aThe designation *1 indicates the reference allele sequence for the analyzed SNP, but may include non-analyzed sequence
variations. bAbraham et al. (2010) – PM: presence of at least one allele *4, *5, or *6; IM: presence of one or two alleles *9, *10, or *41; cTeh et al. (2012) – EM: absence
of alleles *xN, *4, *5, *10, and *14; Het-IM: *1/*10; IM: *10/*10 or heterozygous null alleles (*1/*4, *1/*5, *1/*14); dRegan et al. (2012) – PM: presence of alleles
*3, *4, *6, or *7; IM: *41/*41 or *41/PM; eNewman et al. (2008) – PM: two copies of the CYP2D6*3, CYP2D6*4, or CYP2D6*5 alleles; a group with concomitant
use of a potent CYP2D6 inhibitor in wild-type individuals or moderate inhibitor in heterozygous patients.
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Table 5 | Null associations between polymorphisms in xenobiotic metabolizing enzymes and breast cancer outcomes after chemotherapy.
Gene SNP Reference Population Protocol N Outcome Compared groups
CBR3 730G>A Fan et al. (2008) Neoadjuvant Doxorubicin and
docetaxel
99 Hematological toxicity
or tumor reductiona
GG, GA, and AA
CYP2B6 *3, *5, *8 Bray et al. (2010) Adjuvant AC 230 DFS and toxicity *1/*1 vs. any variant
*2, *3, *4, *5,
*8, and *9
Gor et al. (2010) Adjuvant CAF (+ CTX/thiotepa) 350 DFS *1/*1 vs. any variant
*9 Yao et al. (2010) Adjuvant CAF or CMF 449 Hematological toxicity GG vs. GT or TT
CYP2C8 *1, *2, *3, and
*4
Rizzo et al. (2010) Adjuvant,
neoadjuvant,
metastatic
Taxanes 95 Hematological toxicity,
neurotoxicity, and
hypersensitivityb
*1/*1 vs. any variant
CYP2C9 *2 and *3 Bray et al. (2010) Adjuvant AC 230 BCSS and toxicity *1/*1 vs. any variant
Gor et al. (2010) Adjuvant CAF (+ CTX/thiotepa) 350 DFS *1/*1 vs. any variant
CYP2C19 *2 Bray et al. (2010) Adjuvant AC 230 BCSS and toxicity *1/*1 vs. any variant
CYP2D6 *10 Gor et al. (2010) Adjuvant CAF (+ CTX/thiotepa) 350 DFS G/G vs. G/A vs. A/A
CYP3A4 *4 Tsai et al. (2009) Adjuvant or
neoadjuvant
TEC 59 Toxicity *1/*1 vs. *1/*4
*5 Tsai et al. (2009) Adjuvant or
neoadjuvant
TEC 59 Toxicity *1/*1 vs. *1/*5
*18 Tsai et al. (2009) Adjuvant or
neoadjuvant
TEC 59 Toxicity *1/*1 vs. *1/*18
*1B Yao et al. (2010) Adjuvant CAF or CMF 456 Hematological toxicity *1/*1 vs. *1/*1B or
*1B/*1B
*1G Zhang et al. (2011) Neoadjuvant EPI and CTX 120 Pathological response
and toxicity
CC vs. CT vs. TT
CYP3A5 *3 Bray et al. (2010) Adjuvant AC 230 BCSS and toxicity *1/*1 vs. any variant
Gor et al. (2010) Adjuvant CAF (+ CTX/thiotepa) 350 DFS *1/*3, *1/*1, *3/*3
Zhang et al. (2011) Neoadjuvant EPI and CTX 120 Pathological response
and toxicity
*6 Gor et al. (2010) Adjuvant CAF (+ CTX/thiotepa) 350 DFS *1/*1 vs. *1/*6
CYP3A7 *2 Zhang et al. (2011) Neoadjuvant EPI and CTX 120 Pathological response
and toxicity
AA, AT, TT
GSTA1 rs3957356-
69A>G
Yao et al. (2010) Adjuvant CAF or CMF 414 Hematological toxicity GG vs. GA or AA
GSTM1 Null Gor et al. (2010) Adjuvant CAF (+ CTX/thiotepa) 350 DFS Null vs. non-null
Oliveira et al. (2010) Neoadjuvant FEC 40 Pathological response Null vs. non-null
Mishra et al. (2011) Neoadjuvant CAF – docetaxel 45 Pathological response Null vs. non-null
Saadat et al. (2012) Neoadjuvant CAF or TAC 101 Pathological response Null vs. non-null
GSTO2 rs156697
(Asn142Asp)
Saadat et al. (2012) Neoadjuvant CAF or TAC 101 Pathological response Asn/Asn, Asn/Asp,
Asp/Asp
GSTP1 Ala114Val Bewick et al. (2008) Metastatic MITOX and CTX 95 PFS and BCSS AA, AG, GG
Ile105Val Bewick et al. (2008) Metastatic MITOX and CTX 95 PFS and BCSS CC, CT, TT or GG,
GA, AA
Gor et al. (2010) Adjuvant CAF (+ CTX/thiotepa) 350 DFS GG, GA, AA
Oliveira et al. (2010) Neoadjuvant FEC 40 Pathological response Ile/Val vs. Ile/Ile
Yao et al. (2010) Adjuvant CAF or CMF 874 DFS GG, GA, AA
(Continued)
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Table 5 | Continued
Gene SNP Reference Population Protocol N Outcome Compared groups
GSTT1 Null Gor et al. (2010) Adjuvant CAF (+ CTX/thiotepa) 350 DFS Null vs. non-null
Oliveira et al. (2010) Neoadjuvant FEC 40 Pathological response Null vs. non-null
Mishra et al. (2011) Neoadjuvant CAF – docetaxel 45 Pathological response Null vs. non-null
Saadat et al. (2012) Neoadjuvant CAF or TAC 101 Pathological response Null vs. non-null
GSTZ1 rs7975
(Glu32Lys)
Saadat et al. (2012) Neoadjuvant CAF or TAC 101 Pathological response Glu/Glu, Glu/Lys,
Lys/Lys
Abbreviations: AC, adriamycin and cyclophosphamide; BCSS, breast cancer-specific survival; CAF, cyclophosphamide, adriamycin, and 5-fluorouracil; CMF, cyclophos-
phamide, metothrexate, and 5-fluorouracil; CTX, cyclophosphamide; DFS, disease-free survival; EPI, epirubicine; FEC, 5-fluorouracil, epirubicine, and cyclophos-
phamide; MITOX, mitoxantrone; OR, odds ratio; OS, overall survival; PFS, progression-free survival; TEC, docetaxel, epirubicine, and cyclophosphamide. aTumor
reduction was defined as ≥25% tumor reduction after the first cycle of doxorubicin; bThe hypersensitivity reactions were characterized by acute dyspnea, flushing of
the face, chest constraint, hypotension, and rash.
the activity of CYP2D6 enzyme, characterized individual metab-
olizing phenotypes (Tables 1 and 2). Although some studies have
suggested that reduced CYP2D6 enzymatic activity might con-
tribute for higher risk of breast cancer recurrence (Table 1), the
recent results of the large studies by Abraham et al. (2010) and
Regan et al. (2012) indicate no significant differences in relation
to breast cancer-specific survival, either for poor or intermediate
CYP2D6 metabolizers, which were characterized based on alleles
∗3, ∗4, ∗5, ∗6, ∗7, ∗10, and ∗41 (Table 2).
With regards to other polymorphisms that could affect tamox-
ifen metabolism, there are fewer studies available, and none of
them are based on multicenter large populations. In addition, the
published data are more diverse in relation to the polymorphisms
and to the outcomes that were analyzed, with some polymor-
phisms being evaluated in only one study. Therefore, the available
information does not support combined analyses, and any general
conclusion is only tentative.
The only study involvingCYP2C8 (alleles ∗3 and ∗4) orCYP2C9
(alleles ∗2 and ∗3) was the work by Jernström et al. (2009),
who described an increased risk of early breast cancer-related
deaths associated with the haplotype CYP2C8∗1/∗3/CYP2C9∗1/∗2
(Table 1). According to the authors, the effect appears to be driven
by CYP2C8∗3, which presents strong, but not complete linkage
disequilibrium with CYP2C9∗2. The authors found no significant
effects associated withCYP2C8∗4,CYP2C9∗2, orCYP2C9∗3, when
evaluated independently (Table 2). With regards to CYP2C19,
Okishiro et al. (2009) analyzed the alleles ∗2 and ∗3, Ruiter et al.
(2010) analyzed only the allele ∗2, and Moyer et al. (2011) analyzed
the allele ∗17. Ruiter et al. (2010) were the only ones to describe
an apparent protective effect for the allele ∗2, with longer breast
cancer-specific survival among patients carrying any variant geno-
type (Table 1).CYP3A5 was analyzed by Goetz et al. (2005), Tucker
et al. (2005), and Wegman et al. (2007). Tucker et al. (2005) eval-
uated CYP3A5∗3 and CYP3A5∗6, whereas the other two studies
analyzed only CYP3A5∗3. Wegman et al. (2007) reported a sig-
nificantly improved recurrence-free survival among CYP3A5∗3-
homozygous patients (Table 1), which was not seen by Goetz et al.,
2005; Table 2). Tucker et al. (2005) did not evaluate response out-
comes, and reported no significant association between CYP3A5
polymorphisms and adverse events during tamoxifen treatment
(Table 2). SULT1A1 was studied by Nowell et al. (2002), Weg-
man et al. (2005), Wegman et al. (2007), and Moyer et al. (2011).
The first three studies evaluated the polymorphism SULT1A1∗2,
whereas Moyer et al. (2011) analyzed the number of gene copies
in breast tumors. The study by Nowell et al. (2002) was the only
one to report a significant effect of the homozygous ∗2/∗2 on
patients’ overall survival (Table 1). Wegman et al. (2007) also
reported significant detrimental effects of the variant allele ∗2
on recurrence-free survival after 2 years of tamoxifen treatment
(Table 1), but this association was no longer existent after 5 years of
tamoxifen treatment (Table 2). The polymorphisms UGT1A8∗3,
UGT2B7∗2, and UGT2B15∗2 were analyzed by Ahern et al. (2011),
who found no significant associations between their variant alle-
les and recurrence-free survival in breast cancer patients under
adjuvant or neoadjuvant treatment with tamoxifen (Table 2).
UGT2B15∗2 was also analyzed by Nowell et al. (2002) and Weg-
man et al. (2007). Nowell et al. (2002) were the only ones to report
a significant higher risk of disease progression for patients carrying
the variant allele ∗2 (either in heterozygosis or in homozygosis) in
combination with the genotype SULT1A1∗2/∗2 (Table 1). In con-
clusion, there is no consistency among the few and sparse results
regarding polymorphisms in xenobiotic metabolizing enzymes
different from CYP2D6 and their impact on tamoxifen efficacy
or safety. Taken together, these results do not suggest clinically rel-
evant implications of such pharmacogenetic targets for tamoxifen
treatment.
The published data regarding functional polymorphisms in
xenobiotic metabolizing enzymes and breast cancer chemother-
apy present even greater diversity in design than observed for
studies involving tamoxifen. As expected, these studies involve
different patients’ subgroups, and comprise distinct chemother-
apeutic protocols. The study designs are also very diverse in
the selection of polymorphisms and in analyzed outcomes, with
some studies evaluating response outcomes, whereas others focus
only in adverse effects. Table 3 summarizes all the available
data for significant associations with response outcomes. The
compiled information indicates worse outcomes (higher recur-
rence risk or shorter breast cancer-specific survival) for the
polymorphisms CYP1A1m2, CYP1B1∗3, CYP2B6∗2, ∗4, and ∗9,
CYP3A4∗1B, GSTP1A313G, and UGT2B7His268Tyr, whereas a
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beneficial effect is observed for the variant genotype GSTA1∗B/∗B
(better overall survival) and for the GSTT1Null genotype (longer
breast cancer-specific survival). Bewick et al. (2008) found no
significant effect for GSTP1A313G when evaluated indepen-
dently, but reported a combined effect of GSTP1A313G vari-
ant genotypes and SOD2C16CT variant homozygous genotype
resulting in shorter progression-free survival and breast cancer-
specific survival for patients using mitoxantrone and cyclophos-
phamide.
Table 4 summarizes all the available data for significant asso-
ciations with chemotherapy-related toxicity outcomes. The com-
piled results indicate higher risk of severe hematological reactions
(neutropenia, leucopenia, or thrombocytopenia) for patients with
CBR3 G11A or GSTP1A313G variant genotypes. The other ana-
lyzed polymorphisms (CYP1B1∗3,CYP2B6∗2,CYP3A5∗3) showed
beneficial effects in relation to the risk of hematological tox-
icities for patients using anthracycline-based protocols and/or
taxanes.
Finally, Table 5 summarizes all the null associations involving
polymorphisms in xenobiotic metabolizing enzymes and breast
cancer outcomes after chemotherapy. The compiled data comprise
various studies evaluating many polymorphisms, but, in most
cases, there is only one study for each polymorphism. Because
most studies are based on a relatively small number of patients
using specific protocols, the compiled information is very diffuse
and does not allow definite conclusions or general assumptions.
Therefore, the results must be analyzed independently, considering
the particularities of each study.
The only polymorphisms that were analyzed by at least two
independent studies with similar designs were CYP2B6∗2, ∗3, ∗5,
∗8, and ∗9,CYP2C9 ∗2 and ∗3, and CYP3A5∗3, which were studied
by Bray et al. (2010) and Gor et al. (2010), evaluating survival in
patients under adjuvant chemotherapy with anthracycline-based
protocols. GSTM1null was also studied under similar conditions
by Oliveira et al. (2010), Mishra et al. (2011), and Saadat et al.
(2012), who evaluated the pathological response to neoadjuvant
chemotherapy with anthracyclines and taxanes. In the case of
CYP2B6∗2, Bray et al. (2010) reported a significant association
between the heterozygous variant genotype and shorter time to
progression for patients under adjuvant chemotherapy with the
protocol AC (Table 3), whereas Gor et al. (2010) found no sig-
nificant effect on disease-free survival for patients under adjuvant
chemotherapy with the protocol CAF (+CTX/Thiotepa; Table 5).
In the case of CYP3A5∗3, Tsai et al. (2009) found that patients
carrying the heterozygous ∗1/∗3 genotype demonstrated more
side effects of fever, pleural effusion, and febrile neutropenia than
those with the homozygous ∗3/∗3 genotype (Table 4). Bray et al.
(2010), evaluating dose delays in adjuvant chemotherapy with AC,
found no significant associations with CYP3A5∗3 variant alleles
(Table 5), which the authors interpreted as no significant differ-
ences in clinically relevant toxicities. Zhang et al. (2011), evaluating
severe toxicities (grade 3 or 4) to neoadjuvant chemotherapy
with EPI and CTX, also found no significant associations with
CYP3A5∗3 variant alleles (Table 5). It is not clear whether the dis-
crepancies in the association results reported by different studies
involving the same polymorphisms can be attributed to distinct
chemotherapeutic protocols, or to other uncontrolled causes of
variability.
DISCUSSION
The field of pharmacogenetics (or pharmacogenomics) has devel-
oped with the goal of identifying genetic causes of interindividual
differences in pharmacological response, and of using such genetic
information to predict one individual’s profile of drug safety and
efficacy. In this regard, pharmacogenetic studies are designed to
evaluate the correlation between genotypes and phenotypes, and,
therefore, provide scientific evidence for the implementation of
individualized drug prescriptions, as part of a conduct of person-
alized medicine. Nevertheless, the characterization of phenotypes
may not be easy to accomplish, especially in clinical settings, or
when they require invasive procedures. In addition, the actual
therapeutic goal is the final clinical outcome, which is, there-
fore, usually taken as the endpoint of pharmacogenetic studies.
One limitation, however, is that clinical outcomes are often the
result of complex and overlapping variables, which may have dif-
ferent genetic and non-genetic causes. As a consequence, the strict
genotype-phenotype correlation may be compromised, and the
results of pharmacogenetic studies may be difficult to interpret.
This is exactly the scenario of breast cancer treatment: although
there are theoretical bases and practical evidences that genetic
influences may indeed affect the pharmacological response, there
is great uncertainty about the usefulness of the genetic informa-
tion to actually predict clinical outcomes and even more on the
confidence of using such individual genetic information to modify
one’s therapeutic conduct.
The first therapeutic target to drive the attention of pharma-
cogenetic studies to breast cancer therapy was CYP2D6 in view of
its apparent strong genotype-phenotype correlation. Thus, vari-
ous literature reports indicated that genetic variations in CYP2D6
affect the availability or the functional activity of the correspond-
ing enzyme (Jin et al., 2005), and that such variations in the
enzymatic activity ultimately lead to altered levels of tamoxifen
metabolites (Lim et al., 2007, 2011; Kiyotani et al., 2010; de Graan
et al., 2011; Irvin et al., 2011; Mürdter et al., 2011). In addition,
parallel observations indicated that altered levels of the most active
tamoxifen metabolite, endoxifen, result in reduced binding to the
estrogen receptor and to lower signaling transduction (Coezy et al.,
1982; Lim et al., 2006). Taken together, these results have reinforced
the notion thatCYP2D6 polymorphisms could be useful to predict
one individual’s response to tamoxifen, and that CYP2D6 geno-
typing might help the selection of the antiestrogenic drug or the
definition of tamoxifen dosing. The promises of this rationale in
relation to possible improvements in breast cancer outcomes has
led to the expansion of pharmacogenomic studies to other ther-
apeutic targets in breast cancer antineoplastic chemotherapy, as
well as to other targets of tamoxifen pharmacokinetics.
The evaluation of the literature production involving the phar-
macogenetics of breast cancer indicates a great number of stud-
ies. The current review, which was focused on pharmacokinetic
targets, and more specifically, on functional polymorphisms of
xenobiotic metabolizing enzymes, has initially retrieved 158 refer-
ences on the subject. Although the criteria for the systematic search
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included the mention to xenobiotic metabolizing enzymes in the
article’s title or abstract, most of the retrieved documents explored
different targets as their main research subject. The most frequent
targets besides xenobiotic metabolizing enzymes that were identi-
fied in the current search were drug transporters, which might
contribute to antineoplastics’ pharmacokinetics, affecting drug
distribution and disposition, and aromatases, which modulate the
availability of estrogens, and the estrogen receptor. The selection
of documents exploring functional polymorphisms of xenobiotic
metabolizing enzymes resulted in 43 original articles, 23 devoted
to tamoxifen, and 20 dealing with various antineoplastic proto-
cols. Among the articles involving tamoxifen, CYP2D6 was the
main pharmacogenetic target, whereas multiple xenobiotic metab-
olizing enzymes were explored with regards to different cytotoxic
antineoplastics. This conjunct of original articles on the pharma-
cogenetics of breast cancer is still relatively limited in number and
very diverse in design. Consequently, general conclusions are dif-
ficult to extract at this point, and no clear recommendations can
be made for application in clinical practice. Nevertheless, the use
of the same terms for bibliographic search without the restriction
to original articles indicates that 24 reviews were published on
the subject in the same period of time. Although the analysis of
the reviews was not part of our systematic search, an overview of
the publications indicates that CYP2D6 predominates as the cho-
sen subject, probably as a reflex of the great enthusiasm after the
earliest studies. Some of the most recent reviews already include
data on other xenobiotic metabolizing enzymes, but no systematic
review had been presented before.
The studies on CYP2D6 polymorphisms and their influences
on tamoxifen efficacy show many discrepancies, which can be
accounted to multiple factors, including variations in study design,
in the definitions of breast cancer disease, and in the population
characteristics. Thus, in relation to study design, differentCYP2D6
polymorphisms are analyzed, and some studies use tumor tis-
sue for genotype assessment, which can compromise the accurate
characterization of the number and types of CYP2D6 alleles. There
are also variations in the therapeutic regimen, including adjuvant,
neoadjuvant and palliative treatment, and evaluation of different
disease outcomes. The prescribed tamoxifen dose may also vary,
and, in most studies, there is no control or documentation of drug
adherence and of concomitant use of CYP2D6 inhibitors. The
population characteristics also present great variability, includ-
ing different ethnic and cultural backgrounds, which can interfere
with risk estimates. Finally, the percentage of postmenopausal
women may also be an interfering factor, if there is no control of
the use of aromatase inhibitors after the completion of tamoxifen
treatment.
A meta-analysis published by Seruga and Amir (2010) ana-
lyzed data from 10 studies assessing CYP2D6 genotype and clinical
outcomes in breast cancer. The authors found significant hetero-
geneity in the definition of comparison groups between studies,
but suggested that normal CYP2D6 function was associated with
a trend toward improved disease-free survival (HR 2.07, 95% CI
0.96–4.49, P = 0.06). The most recent work on the subject, by
Regan et al. (2012), enrolled a large number of postmenopausal
patients treated with tamoxifen for 5 years, as part of the BIG 1–98
trial, and showed no association between CYP2D6 metabolizing
phenotype and the risk of recurrence (characterized by the breast
cancer-free interval), with or without previous chemotherapy. The
patients who were identified as poor or intermediate metabolizers
(based on alleles ∗2, ∗3, ∗4, ∗6, ∗10, ∗17, and ∗41) did not have
worse disease outcomes than extensive metabolizers, or higher
chance of presenting hot flushes as side effects. The authors argued
that CYP2D6 metabolizing phenotype is not the correct surro-
gate for predicting symptoms or outcome of tamoxifen-treated
postmenopausal women, and advocated that CYP2D6 pharmaco-
genetic testing to determine whether adjuvant tamoxifen should
be given to postmenopausal women with endocrine-responsive
breast cancer is not justified (Regan et al., 2012). Although very
large in the number of patients enrolled, and with a well-planned
prospective design, one limitation of the work by Regan et al.
(2012), as acknowledged by the authors, is the use of tumor sam-
ples for genotyping, which could lead to some misclassification
of metabolizing phenotypes. In addition, the trial did not pro-
vide data on concomitant medications, and therefore, a possible
interference of CYP2D6 inhibitors cannot be ruled out.
Two other large studies involving breast cancer survivors who
used tamoxifen (Abraham et al., 2010; Madlensky et al., 2011) also
suggested the lack of association between CYP2D6 genotypes, or
estimated CYP2D6 metabolizing phenotypes, and breast cancer
outcomes. Thus,Abraham et al. (2010) found that only the allele ∗6
was associated with lower breast cancer-specific survival, whereas
the other alleles (∗4, ∗5, ∗9, ∗10, and ∗41) had no significant effects.
Madlensky et al. (2011) found no significant associations between
CYP2D6 metabolizing phenotypes and the risk of breast cancer
recurrence or second breast cancer. The latter authors, however,
reported that patients with endoxifen concentrations lower than
5.97 ng/mL were at higher risk of breast cancer recurrence, and that
the proportion of decreased CYP2D6 metabolizing phenotype was
higher in this group. In addition to CYP2D6 metabolizing pheno-
type, the authors identified other variables, such as excess weight
and low tamoxifen levels (suggesting failures in adherence), which
were associated with low endoxifen levels, but not independently
associated with breast cancer outcomes. The authors suggested the
existence of a non-linear dose-response effect for tamoxifen, and
proposed that a threshold of endoxifen must be achieved for the
therapeutic effect of tamoxifen. Finally, the authors argued that
the metabolizing phenotype alone is not enough to determine
whether tamoxifen is of potential benefit to any individual patient
(Madlensky et al., 2011).
Another aspect with pharmacogenetic interest in relation to
tamoxifen is the occurrence of side effects, especially hot flushes,
which are intrinsically correlated with the suppression of estrogen
signaling, and thus expected to be associated with endoxifen levels.
Some authors have proposed that hot flushes could serve as surro-
gates of tamoxifen efficacy, and that their absence could indicate
patients at higher risk of recurrence (Cuzick et al., 2008; Mortimer
et al., 2008). As a logical consequence, it has been hypothesized
that poor CYP2D6 metabolizers would be less likely to experience
moderate to severe hot flushes (Goetz et al., 2005; Henry et al.,
2009), whereas, in contrast, extensive metabolizers would be more
prone to prematurely discontinue tamoxifen, possibly as a con-
sequence of severe hot flushes (Rae et al., 2009). The assumed
correlation between CYP2D6 metabolizing phenotypes and hot
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flushes, however, was based on few and weak associations, with
no (or only border-line) statistical significance, which were not
validated in the recent large prospective study by Regan et al.
(2012). Unfortunately, there have been no similar large observa-
tional studies evaluating CYP2D6 metabolizing phenotypes and
hot flushes as possible causes of non-adherence or non-persistency
to tamoxifen treatment. It would be also interesting to have stud-
ies evaluating the correlation between endoxifen levels and the
occurrence of severe hot flushes.
The metabolism of tamoxifen involves other metabolizing
enzymes than CYP2D6, such as CYP3A4/5, 2C8/9, SULT1A1,
UGT1A8, UGT2B7, and UGT2B15, which might also have an
impact on the availability of endoxifen and other metabolites,
and therefore contribute for the heterogeneity in breast cancer
outcomes. However, there are few studies evaluating genetic poly-
morphisms on such metabolic activities and their consequences
on tamoxifen efficacy. In addition, the assumption that tamoxifen
efficacy is mainly dependent on the availability of endoxifen must
also be considered with a certain caution. Although endoxifen has
greater affinity for the estrogen receptor than tamoxifen or N -
desmethyl-tamoxifen (Coezy et al., 1982; Jordan, 1982; Robertson
et al., 1982), and higher plasma concentrations than 4-hydroxy-
tamoxifen (Johnson et al., 2004; Lim et al., 2005), it has been esti-
mated that tamoxifen and its metabolites other than endoxifen are
capable of nearly saturating estrogen receptors, with 99.94% occu-
pancy (Dowsett and Haynes,2003). Therefore, impaired tamoxifen
metabolism may not represent a full limitation for tamoxifen
efficacy, other cellular mechanisms must be considered when eval-
uating tamoxifen resistance. Thus, Kim et al. (2011) have shown
that tumor cells with low mRNA expression of the estrogen recep-
tor (ESR1) present increased tamoxifen resistance when compared
to cells with high-level mRNA expression, regardless of endox-
ifen concentrations. Finally, recent studies have suggested that
tamoxifen and its metabolites may have secondary pharmacologi-
cal actions, such as blockade of voltage-dependent Ca2+ channels
(Kuo et al., 2012), vasodilation (Montenegro et al., 2011), and aro-
matase inhibition (Lu et al., 2012). The possible impact of such
additional pharmacological mechanisms on breast cancer is not
known yet.
The evaluation of studies involving chemotherapeutic pro-
tocols for breast cancer therapy indicates that many xenobiotic
metabolizing enzymes other than CYP2D6 are also being consid-
ered as possible pharmacogenetic targets. These studies indicate
great diversity of antineoplastic protocols and a balanced inter-
est in both efficacy and toxicity. The number of studies, however,
is still very limited, with only one or very few studies for each
pharmacogenetic target, and no confirmation of positive associ-
ations. The only exception appears to involve GSTP1 Ile105Val,
since three different studies (Zárate et al., 2007; Yao et al., 2010;
Zhang et al., 2011), exploring anthracycline-based protocols, sug-
gest higher risk of severe hematological toxicity (neutropenia or
leucopenia) for patients with variant genotypes. Although there
are some inconsistencies regarding the heterozygous genotype,
the combined results appear to indicate that the presence of valine
instead of isoleucine, which results in decreased enzymatic activity
(Watson et al., 1998), would favor higher plasma concentrations of
the chemotherapeutic drugs, with consequent increased toxicity.
Such increased toxicity, as an apparent consequence of increased
plasma concentrations, does not seem to have a direct correlation
with better response profile. Thus, although Zhang et al. (2011)
have reported better pathological response for patients with the
G/G (Val/Val) genotype after neoadjuvant therapy, Huang et al.
(2008) found that patients with variant genotypes had higher
rates of early relapse after adjuvant treatment, and other authors
found no significant effects of the GSTP1 Ile105Val polymor-
phism on the therapeutic response after adjuvant (Gor et al.,
2010; Yao et al., 2010) or neoadjuvant treatment (Oliveira et al.,
2010).
The above results point an important aspect of pharmacoge-
netic studies in clinical oncology, which is the apparent higher
variability in the results involving response outcomes than in those
related to drugs’ toxicities. This is not surprising considering that,
in addition to the subjects’ polymorphisms, tumors might also
present mutations, as well as epigenetic variations that could affect
cellular response to chemotherapy. Secondly, an individual clinical
response also involves many non-genetic factors that are difficult
to control, such as lifestyle, comorbidities, drug interactions, and
treatment adherence. Finally, in the case of breast cancer, clin-
ical outcomes have a long time frame, which make them more
difficult to study in a controlled design. Although it is logical
that prospective observational studies combining the evaluation
of pharmacogenetic data and non-genetic patients’ characteristics
would be ideal for modeling breast cancer clinical outcomes, their
practical implementation is certainly a challenge.
Another important issue raised by the example of the results
involving GSTP1 Ile105Val involves the translation of pharmaco-
genetic data into the clinical practice of oncology. Let’s assume
that a genotype-phenotype is established, and that it involves a
pharmacokinetic target, with an apparent plasma concentration-
dependent relationship. In such scenario, should one individual’s
dose be adjusted based on the identified genotype? For example,
should patients with the homozygous variant GSTP1 genotype
receive lower doses as an attempt to reduce their risk of severe
neutropenia, and therefore avoid treatment delays or interruption
that could compromise the final response outcomes? Although the
genotype-phenotype relationship might be recognized when eval-
uating the risk estimates in a population, there is no absolute cor-
respondence between genotypes and outcomes at the individual
level. In addition, there is certainly great concern about reducing
the dose, and consequently increasing the risk of lower response.
Thus, it seems unlikely that such prophylactic dose adjustments
based on an individual genotype would even be tested in a clini-
cal trial, and ultimately incorporated for oncological treatments.
Alternatively, should patients at estimated higher risk of toxicity
receive some prophylactic or supportive treatment? For example,
in the case of patients with the variant GSTP1 genotype, should
stimulating factors be considered as a strategy to minimize their
risk of neutropenia? There is no doubt that the idea of being able to
choose a drug guided by an individual genotype, as it was initially
considered for tamoxifen vs. aromatase inhibitors, is more appeal-
ing as a practical pharmacogenetic conduct in oncology than the
hard and risky task of defining one individual’s antineoplastic
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dose. Nevertheless, the current recommendations of the Ameri-
can Society of Clinical Oncology (ASCO) do not include routine
CYP2D6 testing to select the endocrine therapy (Burstein et al.,
2010).
CONCLUSION AND PERSPECTIVES
The application of pharmacogenetics to predict breast cancer ther-
apeutic outcomes and to select one individual’s chemotherapeutic
protocol is still far from clinical routine. Most studies used the
candidate-gene approach, and evaluated single or few SNPs in
metabolic pathways. In addition, because of the difficulties of
conducting large trials, most studies explored the most common
genetic variations. Although some very interesting results have
been produced, no clear practical recommendations are recog-
nized yet. The current challenge is to simultaneously evaluate
multiple genes and pathways, including rarer variants, and to con-
sider their combined effects on drug efficacy and toxicity. Such
endeavor will require large, multicentric studies, and longer and
well-controlled follow-ups, in order to produce reliable informa-
tion, aiming at consequent practical applications for breast cancer
therapy.
These above conclusions regarding the constraints for clinical
applicability of pharmacogenomic data in breast cancer manage-
ment meet the consensus view on the use of qualifying biomarkers
in drug safety (Agúndez et al., 2012). It appears, thus, that the lim-
itations of pharmacogenomic studies are not a particularity of
Oncology, and that the use of genetic information as biomarkers
requires medical and scientific consensus and the development of
adequate guidelines for clinical practice. Research consortia appear
to be good opportunities to explore these goals.
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